Transfuse Lovotibeglogene in Periph Vein, Perc, New Tech 9

This code represents the administration of Lovotibeglogene Autotemcel, a gene therapy product, directly into a patient's peripheral vein. This procedure involves the infusion of genetically modified autologous hematopoietic stem cells to treat specific genetic disorders. The "New Technology Group 9" designation indicates its novel and advanced nature.

This code is used when a patient receives Lovotibeglogene Autotemcel via a peripheral intravenous line. This typically occurs in the context of treating beta-thalassemia or sickle cell disease, where the patient's own stem cells have been modified ex vivo and are then reinfused. It is crucial to confirm the specific gene therapy product administered is Lovotibeglogene Autotemcel.

• Verify that the documentation explicitly states the administration of Lovotibeglogene Autotemcel.
• Confirm the route of administration was a peripheral vein and the approach was percutaneous.
• Do not use this code for other gene therapy products or different routes of administration.